Context Therapeutics Inc (CNTX NASDAQ) stock market data APIs
$2.2888
0.18(7.9%)
as of February 4, 2026
Try our APIs with
free plan!
Context Therapeutics Inc Financial Data Overview
Price chart is built with
Anychart
Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. The company was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.
Prev. Close
2.2888
Open
2.4664
High
2.4801
Low
2.0708
52 wk Range
0.49-2.85
Market Cap
211 M
Shares Outstanding
91 879 K
EPS
-0.1
Beta
1.945
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Context Therapeutics Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Context Therapeutics Inc data using free add-ons & libraries
Get Context Therapeutics Inc Fundamental Data
Context Therapeutics Inc Fundamental data includes:
- Net Revenue:
- EBITDA: -30 193 288
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-11-06
- EPS/Forecast: -0.09
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Context Therapeutics Inc News
New
Cancer Drug Developers Secure Regulatory Clarity as FDA Reshapes Approval Standards
VANCOUVER, British Columbia, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Equity-Insider.comNews Commentary – The FDA is moving to require just one clinical trial for new drug approvals, signaling a dramatic...
Context Therapeutics Highlights CT-95 and CT-202 Programs at 2025 SITC Annual Meeting
PHILADELPHIA, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging (�...
Context Therapeutics GAAP EPS of -$0.10 misses by $0.01
* Context Therapeutics press release [https://seekingalpha.com/pr/20295545-context-therapeutics-reports-third-quarter-2025-operating-and-financial-results] (CNTX [https://seekingalpha.com/symbol/CNT...
Context Therapeutics Reports Third Quarter 2025 Operating and Financial Results
Ongoing Phase 1 trial of CTIM-76 (CLDN6 x CD3) demonstrates encouraging antitumor activity and safety Ongoing Phase 1 trial of CT-95 (MSLN x CD3) is approaching target dose levels Cash and cash equi...
Get Context Therapeutics Inc fresh news feed via Financial News API
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
